New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Immutep securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky Accessibility StatementSkip NavigationImmutep Stock Collapsed Up to 90% After Independent Committee Recommended Halting Lead Phase III Trial -- Levi & Korsinsky Investigates Potential Securities Law ViolationsNEW YORK, March 25, 2026 /PRNewswire/ -- Immutep Ltd. (NASDAQ: IMMP) shares lost approximately 80% to 90% of their valu ...

Core Viewpoint - Immutep Limited is under investigation for potential violations of federal securities laws following a significant drop in share price due to negative results from a clinical trial analysis [1][3]. Group 1: Company Developments - On January 30, 2026, Immutep filed a 6-K with the SEC indicating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and highlighted "strong operational progress" for the trial [2]. - The interim futility analysis announced on March 13, 2026, indicated that the drug was unlikely to succeed, leading to a recommendation to stop the study [2][3]. - The discrepancy between the positive guidance in January and the negative outcome in March resulted in a share price decline of up to 90% in a single session [3]. Group 2: Legal and Financial Implications - Levi & Korsinsky has initiated an investigation into Immutep Limited for potential recovery options for investors who suffered losses on their securities [1][4]. - The firm has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Immutep Limited due to alleged violations of securities laws following the discontinuation of a key clinical trial, which led to a significant drop in the company's stock price [1][2]. Group 1: Investigation Details - The investigation focuses on whether Immutep issued false or misleading statements or failed to disclose important information to investors [2]. - On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa due to a planned interim futility analysis [2]. - Following this announcement, Immutep's American Depositary Receipts (ADRs) fell by more than 82.4% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights free of charge [3].

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Immutep securities may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 2: Company News and Stock Impact - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in- ...

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky Accessibility StatementSkip NavigationImmutep Reported TACTI-004 Futility Analysis Was "On Track" in January 2026 -- Weeks Later the Trial Was Halted After Failing to Meet Efficacy EndpointsNEW YORK, March 18, 2026 /PRNewswire/ -- Shareholders of Immutep Ltd. (NASDAQ: IMMP) who lost money are urged to act now. On Janua ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Class Action Details - Investors who purchased Immutep securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - The law firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Company Developments - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Immutep Limited is under investigation for potential securities fraud following the discontinuation of its TACTI-004 Phase III study due to a recommendation from the Independent Data Monitoring Committee (IDMC) [1][3]. Group 1: Company Developments - On March 13, 2026, Immutep announced the IDMC's recommendation to discontinue the TACTI-004 Phase III study evaluating eftilagimod alfa in patients with 1st line non-small cell lung cancer after a planned interim futility analysis [3]. - The IDMC concluded that the trial should be halted based on the available safety and efficacy data, leading to an orderly wind down of the study, including patient follow-up and site closure [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48 per ADR on March 13, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Immutep investors regarding potential securities fraud or unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].